With over a decade of post-marketing surveillance data, the long-term risk profile is better characterized than any other GLP-1 agonist
Salt form confusion, sourcing concerns, and inconsistent quality have raised red flags
Grigg I, Ivashko-Pachima Y, Hait TA, Korenkov V, Touloumi O, Lagoudaki R, et al
This may be because the Food and Drug Administration (FDA) does not regulate dietary supplements and ingredients in transdermal weight loss patches have only been studied for their effectiveness taken orally
GIPs action to augment splanchnic blood flow, potentially affecting nutrient uptake and its involvement in adipose tissue metabolism and suggested central affects in the regulation of appetite as seen in animal models, all remain to be further explored in humans